Margolin DH, Brice NL, Davidson AM, Matthews KL, Carlton MB. A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease. J Pharmacol Exp Ther. 2022 Apr;381(1):33-41. Epub 2022 Feb 2 PubMed.
Recommends
Please login to recommend the paper.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.